Primary pulmonary hypertension, classified as NYHA functional class III

Indication for Iloprost

Population group: Suitable for both men and women, only adults (18 years old or older)

Treatment of adult patients with primary pulmonary hypertension, classified as NYHA functional class III, to improve exercise capacity and symptoms.

For this indication, competent medicine agencies globally authorize below treatments:

15-45 μg in 6-9 divided doses daily

Route of admnistration

Respiratory (Inhalation)

Defined daily dose

15 - 45 ug

Dosage regimen

From 2.5 To 7.5 ug 6 time(s) per day every day

Detailed description

Dose per inhalation session

At initiation of iloprost treatment the first inhaled dose should be 2.5 microgram iloprost as delivered at the mouthpiece of the nebuliser. If this dose is well tolerated, dosing should be increased to 5 microgram iloprost and maintained at that dose. In case of poor tolerability of the 5 microgram dose, the dose should be reduced to 2.5 microgram iloprost.

Daily dose

The dose per inhalation session should be administered 6 to 9 times per day according to the individual need and tolerability.

Duration of treatment

The duration of treatment depends on clinical status and is left to the physician’s discretion. Should patients deteriorate on this treatment intravenous prostacyclin treatment should be considered.

Active ingredient

Iloprost is a synthetic prostacyclin analogue. After inhalation of iloprost direct vasodilatation of the pulmonary arterial bed occur with consecutive significant improvement of pulmonary artery pressure, pulmonary vascular resistance and cardiac output as well as mixed venous oxygen saturation.

Read more about Iloprost

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner